Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Fig. 2

A waterfall plot of the tumor diameter change of target lesions at iBOR from baseline in 75 patients with advanced gastrointestinal tumors with measurable lesions. Dashed lines of + 20% and − 30% indicate thresholds for immune progressive disease (iPD) and immune partial response (iPR), and each bar represents a patient

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us